Comera Life Sciences Holdings, Inc. financial data

Symbol
CMRA, CMRAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
12 Gill Street, Suite 4650, Woburn, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 9, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 64.9 %
Debt-to-equity -72.8 %
Operating Margin -914 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.7 M shares +54.9%
Common Stock, Shares, Outstanding 30.7 M shares +84.6%
Entity Public Float 22.6 M USD
Common Stock, Value, Issued 2.76 K USD +65.7%
Weighted Average Number of Shares Outstanding, Basic 23.1 M shares +44.2%
Weighted Average Number of Shares Outstanding, Diluted 23.1 M shares +44.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1 M USD -42%
Cost of Revenue 265 K USD -31.2%
Research and Development Expense 1.43 M USD -7.29%
General and Administrative Expense 8.45 M USD -18.5%
Operating Income (Loss) -9.15 M USD +14.9%
Nonoperating Income (Expense) 138 K USD
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic 3.28 USD/shares +50%
Earnings Per Share, Diluted 3.28 USD/shares +50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.77 M USD -33.8%
Accounts Receivable, after Allowance for Credit Loss, Current 250 K USD +150%
Assets, Current 2.63 M USD -38.7%
Property, Plant and Equipment, Net 187 K USD -3.04%
Operating Lease, Right-of-Use Asset 162 K USD -55.4%
Assets 3.07 M USD -37.8%
Accounts Payable, Current 1.14 M USD -20.3%
Accrued Liabilities, Current 1.37 M USD
Liabilities, Current 2.93 M USD -14.5%
Operating Lease, Liability, Noncurrent 53.7 K USD
Liabilities 2.97 M USD -24.5%
Retained Earnings (Accumulated Deficit) -41 M USD -28.2%
Stockholders' Equity Attributable to Parent -4.22 M USD -23.1%
Liabilities and Equity 3.07 M USD -37.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.91 M USD +33.6%
Net Cash Provided by (Used in) Financing Activities 1.58 M USD +610%
Net Cash Provided by (Used in) Investing Activities -88.4 K USD
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 30.7 M shares +84.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -414 K USD +84.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.82 M USD -33.2%
Deferred Tax Assets, Valuation Allowance 4.86 M USD +293%
Deferred Tax Assets, Gross 4.96 M USD +257%
Operating Lease, Liability 172 K USD -53.2%
Depreciation 99.4 K USD -4.17%
Payments to Acquire Property, Plant, and Equipment 88.4 K USD
Lessee, Operating Lease, Liability, to be Paid 177 K USD -55.1%
Property, Plant and Equipment, Gross 759 K USD +14.1%
Operating Lease, Liability, Current 172 K USD -12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 123 K USD -13.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 123 K USD -43.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.87 K USD -79.2%
Operating Lease, Payments 54 K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 98.2 K USD -35.2%
Share-based Payment Arrangement, Expense 996 K USD +110%
Interest Expense 5.97 K USD -53%